핵산 증폭 검사 시장 규모, 점유율과 동향 분석 리포트 : 유형별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Nucleic Acid Amplification Testing Market Summary

The global nucleic acid amplification testing market size was estimated at USD 9,956.82 million in 2024 and is projected to reach USD 23,146.69 million by 2033, growing at a CAGR of 9.30% from 2025 to 2033. This growth is primarily driven by several key factors, including the rising prevalence of infectious diseases, a shift toward point-of-care (POC), advancements in molecular diagnostic technologies, decentralized testing, and the growing demand for personalized medicine.

The rising global burden of infectious diseases such as COVID-19, hepatitis, and HIV continues to underscore the importance of rapid and accurate diagnostic tools like NAAT, which offer high sensitivity and specificity. Moreover, continuous technological innovations, such as real-time PCR, isothermal amplification methods, and automated systems, enhance testing efficiency, speed, and accessibility across clinical and non-clinical settings.

For instance, in June 2023, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test, a molecular NAAT designed to detect SARS-CoV-2 genetic material from nasal swabs in symptomatic adults. Notably, this was the first at-home, over-the-counter molecular test for any respiratory illness to be approved using a traditional premarket review pathway. This milestone reflects the ongoing shift toward patient-centered diagnostics and the growing importance of home-based testing in public health surveillance.

Furthermore, the use of NAAT is expanding beyond infectious disease diagnostics to oncology, genetic screening, and pharmacogenomics, highlighting its importance in the era of precision medicine. Governments and healthcare organizations are also investing in early disease detection programs and laboratory infrastructure to help drive market growth. However, challenges such as high testing equipment costs, regulatory complexities, and limited access in low-resource settings continue to impede widespread adoption.

Finally, the global nucleic acid amplification industry is expected to expand steadily as technological innovation, healthcare decentralization, and the pursuit of personalized medicine work together to improve diagnostic capabilities around the world. With continued R&D investment and supportive regulatory frameworks, NAAT is expected to remain a cornerstone of modern molecular diagnostics for the next decade.

Furthermore, increasing awareness and implementing large-scale screening programs, particularly those initiated by governments and healthcare organizations, significantly improves disease detection and management. These initiatives promote regular health check-ups and genetic testing, which increases the use of nucleic acid amplification technologies. The rising prevalence of chronic and genetic disorders, such as cancer, cystic fibrosis, and hereditary blood diseases, has increased the need for precise molecular diagnostic solutions that allow for early detection and targeted treatment planning.

Moreover, the integration of advanced technologies and automation such as artificial intelligence (AI), machine learning, robotics, and microfluidics has significantly improved test sensitivity, throughput, and turnaround time. Automated NAAT systems reduce manual intervention, reduce human error, and improve workflow efficiency, making them more useful in both centralized laboratories and point-of-care (POC) settings. The advancement of portable and multiplexed platforms is increasing the accessibility of molecular testing to resource-constrained regions.

Furthermore, regulatory approvals and funding initiatives by public health authorities, international organizations, and private investors encourage innovation and product commercialization. Accelerated regulatory pathways, public-private partnerships, and government investments in pandemic preparedness have all helped to increase the global availability of cutting-edge NAAT products. These combined factors not only enhance diagnostic infrastructure but also lay the groundwork for long-term market growth.

Global Nucleic Acid Amplification Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global nucleic acid amplification testing market based on type, application, technology, end use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Polymerase Chain Reaction (PCR) Tests
• Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
• Ligase Chain Reaction (LCR) Tests
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Infectious Disease Testing
  • COVID-19 Testing
  • Mosquito-Borne Disease Testing
  • Influenza Testing
  • Sexually Transmitted Infections Testing
  • Hepatitis Testing
  • Tuberculosis Testing
  • Others
• Oncology Testing
• Genetic & Mitochondrial Disease Testing
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Central and Reference Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Nucleic Acid Amplification Testing Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Type
    • 1.1.1.2. Application Segment
    • 1.1.1.3. Technology Segment
    • 1.1.1.4. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Influenza Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Nucleic Acid Amplification Testing Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Type
• 2.3. Application Snapshot
• 2.4. Technology Snapshot
• 2.5. End Use Snapshot
• 2.6. Competitive Landscape Snapshot

Chapter 3. Nucleic Acid Amplification Testing Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Increasing global prevalence and severity of seasonal and zoonotic influenza outbreaks
  • 3.4.2. Rising prevalence of infectious diseases
  • 3.4.3. Advancements in molecular diagnostic technologies
  • 3.4.4. Shift toward point-of-care (POC) and decentralized testing
  • 3.4.5. Growing demand for precision/personalized medicine and genetic diagnostics
• 3.5. Market Restraint Analysis
  • 3.5.1. Shortage of skilled personnel and infrastructure limitations
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Nucleic Acid Amplification Testing Market: Type Estimates & Trend Analysis

• 4.1. Nucleic Acid Amplification Testing Market: Type Movement Analysis
• 4.2. Nucleic Acid Amplification Testing Market by Test Outlook (USD Million)
• 4.3. Polymerase Chain Reaction (PCR) Tests
  • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
  • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Ligase Chain Reaction (LCR) Tests
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Nucleic Acid Amplification Testing Market: Application Estimates & Trend Analysis

• 5.1. Nucleic Acid Amplification Testing Market: Application Movement Analysis
• 5.2. Nucleic Acid Amplification Testing Market by Application Outlook (USD Million)
• 5.3. Infectious Disease Testing
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.2. COVID-19 Testing
    • 5.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.3. Mosquito-Borne Disease Testing
    • 5.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.4. Influenza Testing
    • 5.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.5. Sexually Transmitted Infections Testing
    • 5.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.6. Hepatitis Testing
    • 5.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.7. Tuberculosis Testing
    • 5.3.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.8. Others
    • 5.3.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Oncology Testing
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Genetic & Mitochondrial Disease Testing
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Nucleic Acid Amplification Testing Market: End Use Estimates & Trend Analysis

• 6.1. Nucleic Acid Amplification Testing Market: End Use Movement Analysis
• 6.2. Nucleic Acid Amplification Testing Market by End use Outlook (USD Million)
• 6.3. Hospitals
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Central And Reference Laboratories
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Others
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Nucleic Acid Amplification Testing Market: Regional Business Analysis

• 7.1. Regional Market Snapshot
• 7.2. North America
  • 7.2.1. North America Nucleic Acid Amplification Testing Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.2.2.2. Key Country Dynamics
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Reimbursement Scenario
    • 7.2.2.5. Competitive Scenario
  • 7.2.3. Canada
    • 7.2.3.1. Canada Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.2.3.2. Key Country Dynamics
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Reimbursement Scenario
    • 7.2.3.5. Competitive Scenario
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.2.4.2. Key Country Dynamics
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Reimbursement Scenario
    • 7.2.4.5. Competitive Scenario
• 7.3. Europe
  • 7.3.1. Europe Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.3.2.2. Key Country Dynamics
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Reimbursement Scenario
    • 7.3.2.5. Competitive Scenario
  • 7.3.3. Germany
    • 7.3.3.1. Germany Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.3.3.2. Key Country Dynamics
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Reimbursement Scenario
    • 7.3.3.5. Competitive Scenario
  • 7.3.4. Spain
    • 7.3.4.1. Spain Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.3.4.2. Key Country Dynamics
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Reimbursement Scenario
    • 7.3.4.5. Competitive Scenario
  • 7.3.5. France
    • 7.3.5.1. France Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.3.5.2. Key Country Dynamics
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Reimbursement Scenario
    • 7.3.5.5. Competitive Scenario
  • 7.3.6. Italy
    • 7.3.6.1. Italy Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.3.6.2. Key Country Dynamics
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Reimbursement Scenario
    • 7.3.6.5. Competitive Scenario
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.3.7.2. Key Country Dynamics
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Reimbursement Scenario
    • 7.3.7.5. Competitive Scenario
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.3.8.2. Key Country Dynamics
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Reimbursement Scenario
    • 7.3.8.5. Competitive Scenario
  • 7.3.9. Norway
    • 7.3.9.1. Norway Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.3.9.2. Key Country Dynamics
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Reimbursement Scenario
    • 7.3.9.5. Competitive Scenario
• 7.4. Asia Pacific
  • 7.4.1. Asia-Pacific Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.4.2.2. Key Country Dynamics
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Scenario
    • 7.4.2.5. Competitive Scenario
  • 7.4.3. China
    • 7.4.3.1. China Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.4.3.2. Key Country Dynamics
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Scenario
    • 7.4.3.5. Competitive Scenario
  • 7.4.4. India
    • 7.4.4.1. India Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.4.4.2. Key Country Dynamics
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Scenario
    • 7.4.4.5. Competitive Scenario
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.4.5.2. Key Country Dynamics
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Reimbursement Scenario
    • 7.4.5.5. Competitive Scenario
  • 7.4.6. Thailand
    • 7.4.6.1. Thailand Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.4.6.2. Key Country Dynamics
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Reimbursement Scenario
    • 7.4.6.5. Competitive Scenario
  • 7.4.7. Australia
    • 7.4.7.1. Australia Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.4.7.2. Key Country Dynamics
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Reimbursement Scenario
    • 7.4.7.5. Competitive Scenario
• 7.5. Latin America
  • 7.5.1. Latin America Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.5.2.2. Key Country Dynamics
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. Competitive Scenario
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.5.3.2. Key Country Dynamics
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Competitive Scenario
• 7.6. MEA
  • 7.6.1. MEA Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.6.2.2. Key Country Dynamics
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. Competitive Scenario
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.6.3.2. Key Country Dynamics
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. Competitive Scenario
  • 7.6.4. UAE
    • 7.6.4.1. UAE Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.6.4.2. Key Country Dynamics
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. Competitive Scenario
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Nucleic Acid Amplification Testing Market, 2021 - 2033 (USD Million)
    • 7.6.5.2. Key Country Dynamics
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
  • 8.2.1. New Product Launch
  • 8.2.2. Partnerships
  • 8.2.3. Acquisition
  • 8.2.4. Collaboration
  • 8.2.5. Funding
• 8.3. Key Company Market Share Analysis, 2024
• 8.4. Company Heat Map Analysis
• 8.5. Company Profiles
  • 8.5.1. F. Hoffmann-La Roche Ltd
    • 8.5.1.1. Company Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Molbio Diagnostics Limited
    • 8.5.2.1. Company Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Becton, Dickinson and Company
    • 8.5.3.1. Company Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Danaher Corporation
    • 8.5.4.1. Company Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Abbott Laboratories
    • 8.5.5.1. Company Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Illumina, Inc.
    • 8.5.6.1. Company Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Siemens Healthineers
    • 8.5.7.1. Company Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. bioMerieux SA
    • 8.5.8.1. Company Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Bio-Rad Laboratories, Inc.
    • 8.5.9.1. Company Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Seegene Inc.
    • 8.5.10.1. Company Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives